INTRODUCTION
============

Amino acids play essential roles in protein synthesis, which promotes cell growth and proliferation in both normal cells and cancer cells \[[@b1-enm-2020-35-2-227]--[@b4-enm-2020-35-2-227]\]. Nonessential amino acids are synthesized from essential amino acids; however, essential amino acids cannot be synthesized *de novo*. Amino acids, particularly essential amino acids, are required to be taken up by various cells via different amino acid transporters. Among the 20 standard amino acids, 11 are nonessential: alanine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, proline, serine, tyrosine, and arginine; the remaining nine are essential: histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and valine.

Thyroid cancer (TC) is the most frequent endocrine carcinoma, with an incidence of 12.9, 25.8, and 64.1 per 100,000 individuals in the USA (2011 to 2015), Puerto Rico (2011 to 2015), and Korea (2008 to 2010), respectively \[[@b5-enm-2020-35-2-227],[@b6-enm-2020-35-2-227]\]. Most TCs are associated with a low mortality risk, with gradual progression, no clinical metastasis, and an excellent prognosis \[[@b7-enm-2020-35-2-227]\]. Some papillary thyroid carcinomas (PTCs) such as microcarcinoma with very low mortality risk may not require surgical treatment (clinical active surveillance) \[[@b8-enm-2020-35-2-227]--[@b10-enm-2020-35-2-227]\]. However, several PTCs associated with a high mortality risk require treatment including surgery, ^131^I-radiotherapy, and chemotherapy targeting the vascular endothelial growth factor receptor. In particular, anaplastic thyroid cancer (ATC) is associated with a high mortality risk, with a 3-year survival ratio of \<20% \[[@b11-enm-2020-35-2-227],[@b12-enm-2020-35-2-227]\]. This review focuses on amino acid transporters as molecular therapeutic targets and their clinical applications for TC.

AMINO ACID TRANSPORTERS AND THYROID CANCER
==========================================

Transporters are classified into two broad categories based on adenosine triphosphate (ATP) dependence \[[@b13-enm-2020-35-2-227]\]. ATP-dependent transporters, known as ATP-binding cassette (ABC) transporters, hydrolyze ATP to obtain energy for transmembrane translocation of their substrates. Transporters without an ATPase domain, called solute carriers (SLCs), facilitate diffusive transport. Most amino acid transporters are SLCs, and belong to several groups based on their substrates and sodium dependency; however, they have been classified in accordance with their sequence homology. L-type amino acid transporters (LATs) are categorized as system L transporters, which transport neutral amino acids including alanine, asparagine, cysteine, glutamine, glycine, proline, serine, tyrosine, isoleucine, leucine, methionine, phenylalanine, threonine, and valine.

Among amino acid transporters, L-type amino acid transporter 1 (LAT1; *SLC7A5*), LAT2 (*SLC7A8*), LAT3 (*SLC43A1*), LAT4 (*SLC43A2*), alanine-serine-cysteine transporter (ASCT, *SLC1A5*), amino acid transporter B(0,+) (ATB^0+^, *SLC6A14*), cystine/glutamate exchanger (xCT, *SLC7A11*), and cationic amino acid transporter 3 (CTR3, *SLC7A3*) are associated with various cancers ([Table 1](#t1-enm-2020-35-2-227){ref-type="table"}). LAT1 and LAT2 are the first and second system L amino acid transporter isoforms, discovered in 1998 \[[@b14-enm-2020-35-2-227],[@b15-enm-2020-35-2-227]\] and 1999 \[[@b16-enm-2020-35-2-227]--[@b18-enm-2020-35-2-227]\], respectively. In healthy individuals, LAT1 is expressed in the Sertoli cells, kidney distal tubules, pancreatic islet cells, and gastrointestinal organs including the esophagus, stomach, small intestine, and colon \[[@b19-enm-2020-35-2-227]\]. LAT1 is demonstrated strong upregulation in many cancers, and higher upregulation of LAT1 associate with poor survival in various cancers including head and neck squamous cell carcinoma (HNSCC), breast, lung, esophagus, and biliary duct cancers \[[@b20-enm-2020-35-2-227]\]. Furthermore, LAT1 suppression decreases cell growth and proliferation through attenuation of mammalian target of rapamycin (mTOR) signaling in many cancer cells \[[@b20-enm-2020-35-2-227],[@b21-enm-2020-35-2-227]\], and impaired migration and invasion of gastric and prostate cancer cells \[[@b22-enm-2020-35-2-227],[@b23-enm-2020-35-2-227]\]. Thus, LAT1 is a strong candidate for molecular-targeted therapy for various cancers. Furthermore, TC cells reportedly display LAT1 upregulation, thus rendering LAT1 a novel molecular therapeutic target \[[@b24-enm-2020-35-2-227]--[@b27-enm-2020-35-2-227]\].

LAT2 has similar expression patterns as LAT1, being primarily expressed in gastrointestinal organs and the kidney proximal tubule \[[@b19-enm-2020-35-2-227]\]. LAT2-knockout mice display a mild phenotype and almost no visible symptoms except for aminoaciduria \[[@b28-enm-2020-35-2-227]\]. Both LAT1 and LAT2 contain 12 transmembrane domains that form a channel for their substrates \[[@b29-enm-2020-35-2-227]\]. However, it remains unclear whether LAT2 expression levels vary during TC. Badziong et al. \[[@b30-enm-2020-35-2-227]\] reported that LAT2 is upregulated in PTC but its levels remain unchanged in follicular thyroid cancer (FTC) and ATC. However, Barollo et al. \[[@b27-enm-2020-35-2-227]\] reported LAT2 downregulation in medullary thyroid cancer (MTC), a neuroendocrine tumor. Thus far, data on LAT2 expression in TC are controversial.

LAT3 has been isolated through expression cloning from hepatocarcinoma cells \[[@b31-enm-2020-35-2-227]\] and its primary structure is reportedly identical to that of prostate cancer over-expressed gene 1(POV1), which is reportedly upregulated in prostate cancer \[[@b32-enm-2020-35-2-227]\]. The substrate selectivity of LAT3 is similar to that of LAT1; its substrates include isoleucine, leucine, methionine, phenylalanine, and valine ([Table 1](#t1-enm-2020-35-2-227){ref-type="table"}) \[[@b31-enm-2020-35-2-227]\]. LAT3 is upregulated in the liver, skeletal muscle, and pancreas \[[@b31-enm-2020-35-2-227]\] and apparently serves as a critical transporter in several cancers. LAT3 knockdown significantly inhibits the leucine uptake, cell proliferation, and metastasis in human prostate cancer cell lines *in vitro* \[[@b33-enm-2020-35-2-227]\]. LAT3 is potentially associated with cancer cell proliferation and metastasis; however, no study has reported the expression of LAT3 in TC.

LAT4 was identified on the basis of its sequence homology with LAT3 \[[@b34-enm-2020-35-2-227]\]. LAT4 is upregulated in peripheral blood, the placenta, kidney, and spleen \[[@b34-enm-2020-35-2-227]\]. Badziong et al. \[[@b30-enm-2020-35-2-227]\] reported that LAT4 is downregulated in PTC, FTC, and ATC. In contrast, LAT4 is overexpressed in Graves' disease. However, the role of LAT4 in thyroid carcinogenesis remains unclear.

ASCT2, an Na^+^-dependent neutral amino acid transporter encoded by *SLC1A5*, is predominantly localized at the cell membrane \[[@b35-enm-2020-35-2-227]\] and mediates the exchange of amino acid substrates, particularly mediating rapid glutamine uptake in proliferating cancer cells \[[@b36-enm-2020-35-2-227]\]. ASCT2 upregulation worsens the prognosis of HNSCC, clear-cell renal-cell carcinoma, gastric cancer, triple-negative breast cancer, ovarian cancer, and other cancers \[[@b37-enm-2020-35-2-227],[@b38-enm-2020-35-2-227]\]. Kim et al. \[[@b39-enm-2020-35-2-227]\] (2016) reported ASCT2 upregulation in MTC originating from parafollicular cells but not in other TCs of follicular origin, including PTC, FTC, poorly differentiated carcinoma, and ATC.

ATB^0+^ is a member of the Na^+^- and Cl^−^-dependent neurotransmitter transporter family, and is upregulated in the lungs, fetal lungs, trachea, and salivary gland. ATB^0+^ transports both neutral and cationic amino acids, and has approximately 60% amino acid similarity with glycine transporters GLYT1 and GLYT2 \[[@b40-enm-2020-35-2-227]\]. The blockade of ATB^0+^ is associated with a reduction in pancreatic cancer cell proliferation, indicating the potential of ATB^0+^ as a drug target in cancer chemotherapy \[[@b41-enm-2020-35-2-227]\]. However, the role of ATB^0+^ in TC remains unclear.

xCT is a cysteine/glutamate transporter, which plays a key role in glutathione synthesis. xCT overexpression decreases endogenous reactive oxygen species (ROS) levels and increases the migration and invasion of glioblastoma cells \[[@b42-enm-2020-35-2-227]\]. Furthermore, xCT accelerates tumor growth and tumor associated-seizures and helps predict the outcomes of patients with malignant glioma \[[@b43-enm-2020-35-2-227]\]. In PTC, xCT upregulation was reportedly associated with poor survival \[[@b25-enm-2020-35-2-227]\].

CTR3 is a sodium-independent cationic amino acid transporter, which is glycosylated and localized at the plasma membrane \[[@b44-enm-2020-35-2-227]\]. Shen et al. \[[@b25-enm-2020-35-2-227]\] reported that *SLC7A3* expression is associated with extrathyroidal extension, higher cancer stage, BRAF, RAS mutation, and mortality in PTC.

Though the protein expression of amino acid transporters alters in many cancers including TC, gene mutations of amino acid transporters are still unclear. The point mutations in *SLC7A5* were reported just one case with a missense mutation in breast cancer \[[@b45-enm-2020-35-2-227]\]. Bik-Multanowski and Pietrzyk \[[@b46-enm-2020-35-2-227]\] screened for *SLC7A5* mutations in phenylketonuric patients and three polymorphism and one new mutation (G41D) were detected \[[@b47-enm-2020-35-2-227]\]. Recently, *SLC7A8* expression was showed in the mouse inner ear and that abolish of LAT2 resulted in age-related hearing loss \[[@b48-enm-2020-35-2-227]\]. They also reported significant decreases in LAT2 transport activity for patient's variants (p.V302I, p.R418H, p.T402M, and p.V460E) in *SLC7A8*. Gene mutations of amino acid transporters according to TC has not been clarified at the moment.

LAT1 AND THYROID CANCER
=======================

LAT1 is one of the most appropriate candidates for molecular-targeted therapy for TC from follicular cell ([Table 2](#t2-enm-2020-35-2-227){ref-type="table"}). Shen et al. \[[@b25-enm-2020-35-2-227]\] reported that a poor prognosis is associated with *SLC7A5* upregulation in PTC. Hafliger et al. \[[@b24-enm-2020-35-2-227]\] and Enomoto et al. \[[@b26-enm-2020-35-2-227]\] reported the therapeutic potential of the selective LAT1 inhibitor JPH203 in TC. Hafliger et al. \[[@b24-enm-2020-35-2-227]\] reported that LAT1 is overexpressed in PTC and ATC, and LAT1 overexpression is associated with a poor prognosis of PTC \[[@b24-enm-2020-35-2-227]\]. Enomoto et al. \[[@b26-enm-2020-35-2-227]\] reported that LAT1 and co-expressed 4F2hc are overexpressed in ATC patients through immunohistochemical analyses, and LAT1 overexpression is associated with poor outcomes in ATC. Both studies confirmed that JPH203 inhibits the proliferation of human TC cell lines *in vitro*. Furthermore, Hafliger et al. \[[@b24-enm-2020-35-2-227]\] and Enomoto et al. \[[@b26-enm-2020-35-2-227]\] reported the antitumor effect of JPH203 in different *in vivo* models, e.g., v-raf murine sarcoma viral oncogene homolog B1 (BRAF)^V600E^/4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)^H1047R^-double mutant mice that constitute spontaneous ATC models with an activated mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathway, and a xenograft mouse model established using ATC cell line 8505C containing BRAF, PI3K3R1/2, and p53 mutations \[[@b48-enm-2020-35-2-227],[@b49-enm-2020-35-2-227]\]. JPH203 can thus be considered a highly reliable therapeutic candidate for TC, particularly ATC.

Furthermore, LAT1 may be considered a therapeutic target in MTC, which originates from parafollicular cells. Barollo et al. \[[@b27-enm-2020-35-2-227]\] confirmed that LAT1 overexpression in MTC paralleled glucose transporter 1 overexpression and that LAT1 is overexpressed in an MTC cell line, TT, through Western blotting. However, it remains unclear whether inhibiting overexpressed LAT1 attenuates MTC proliferation.

In numerous cancers, LAT1 upregulation is associated with metastasis. In non-small-cell lung cancers, lymph node metastasis-positive squamous cell carcinomas express LAT1, while no positive LAT1 signals have been reported in non-metastatic cells \[[@b50-enm-2020-35-2-227]\]. A group of cells with LAT1 upregulation displayed larger metastatic lesions in gastric carcinoma \[[@b51-enm-2020-35-2-227]\]. LAT1 expression in neuroendocrine tumors was significantly associated with lymph node metastasis \[[@b52-enm-2020-35-2-227]\]. The functional significance of LAT1 in metastasis has been reported. RNAi-mediated LAT1 knockdown inhibited the migration and invasion of gastric cancer cells \[[@b23-enm-2020-35-2-227]\] and a cholangiocarcinoma cell line \[[@b53-enm-2020-35-2-227]\]. 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) reportedly inhibited proliferation and migration in a human epithelial ovarian cancer cell line \[[@b54-enm-2020-35-2-227]\]. Although the positive association between cancer metastasis and LAT1 expression has been reported, no studies have indicated the association between LAT1 overexpression and TC metastasis thus far.

CLINICAL APPLICATION OF LAT1-TARGETING AGENTS
=============================================

LAT1 inhibitors
---------------

BCH is a prototypical non-selective LAT1 inhibitor \[[@b55-enm-2020-35-2-227]\]. BCH inhibits LAT1, thus inhibiting the uptake of L-leucine with an IC50 of 73.1 to 78.8 μM in three cancer cell lines (human oral epidermoid carcinoma, human osteogenic sarcoma, and rat glioma cells) \[[@b56-enm-2020-35-2-227]\]. Because high BCH concentrations are required for inhibiting highly proliferous cancer cells, no clinical trials have been performed thus far. JPH203 (KYT-0353) is a selective LAT1 inhibitor with an IC50 of 0.06 μM for L-leucine \[[@b57-enm-2020-35-2-227]\], strongly inhibiting HT-29 colon cancer cell growth, with an IC50 value of 4.1 μM. In 2017, Kongpracha et al. \[[@b58-enm-2020-35-2-227]\] synthesized another LAT1 inhibitor, SKN103, based on the structure of T3 and reported the inhibition of L-leucine uptake of 4 human cell lines (pancreas ductal adenocarcinoma, squamous cell carcinoma, cervix adenocarcinoma, and adenocarcinomic alveolar basal epithelia) and inhibition of tumor cell growth in two cell lines (pancreas ductal adenocarcinoma, and squamous cell carcinoma); however, no *in vivo* assays have been conducted thus far.

JPH203 was recently evaluated in a first-in-human phase 1 clinical trial (UMIN Clinical Trials Registry UMIN000016546). Okano et al. \[[@b59-enm-2020-35-2-227]\] reported among 17 patients with advanced solid tumors, one patient with biliary tract cancer presented a partial response and five patients with biliary tract cancer or colorectal cancer presented stable disease. Common treatment-related adverse events included malaise, nausea, and a grade 1 or 2 fever. JPH203 is currently being evaluated in a phase 2 clinical trial among patients with advanced biliary tract cancers (UMIN Clinical Trials Registry UMIN000034080). To our knowledge, no LAT1 inhibitor has been clinically assessed for TC, in both follicular cell and parafollicular cells thus far.

Diagnosis via positron emission tomography
------------------------------------------

Imaging analysis of TC has largely been dependent on radioactive iodine such as ^123^I and ^131^I scintigraphy. Positron emission tomography (PET) has greater sensitivity than single-photon imaging (planar and single photon emission computed tomography \[SPECT\]) \[[@b60-enm-2020-35-2-227]\]. Upon uptake of radioactive iodine into follicular cells via the sodium/iodide symporter, positron-labeled ^124^I was developed as a PET tracer to detect TC. These primarily help detect metastatic and recurrent foci of TC after total thyroidectomy, through postoperative ^131^I administration. 2-18F-fluoro-2-deoxy-d-glucose (^18^F-FDG) is a most common tracer for visualizing glucose metabolism through PET. Cancer imaging via ^18^F-FDG PET is based on the observation that most cancers, including TC, metabolize glucose at an abnormally high rate \[[@b61-enm-2020-35-2-227]\]. Therefore, evaluation of glucose metabolism through ^18^F-FDG PET helps differentiate between malignant and benign tumors, staging and diagnosis, treatment, evaluation of therapeutic outcomes, prediction of prognosis, responsiveness assessment, and relapse \[[@b62-enm-2020-35-2-227],[@b63-enm-2020-35-2-227]\]. Moreover, high ^18^F-FDG accumulation is associated with low ^131^I accumulation based on dedifferentiation of the follicular thyroid cell (flip-flop) \[[@b64-enm-2020-35-2-227],[@b65-enm-2020-35-2-227]\]. However, ^18^F-FDG PET sometimes yields false-positive results, especially in Hashimoto thyroiditis and Graves' disease, and false-negative results for brain metastasis because of their high background levels \[[@b62-enm-2020-35-2-227],[@b66-enm-2020-35-2-227]\].

To resolve these issues, amino acid assessment has gained increasing attention as alternative probes instead of glucose measurement via ^18^F-FDG. Representative amino acids or their analogs developed as PET probes are L-3-^18^F-fluoro-α-methyl tyrosine (^18^F-FAMT), 6-18F-fluoro-L-3,4-dihydroxy-phenylalanine (^18^F-DOPA), L-\[11C-methyl\] methionine (^11^C-MET), O- (2-\[18F\]fluoroethyl)-l-tyrosine (^18^F-FET), and ^18^F-NKO-035. ^18^F-NKO-035, a LAT1-selective substrate, was recently developed as an anti-cancer agent at Osaka University \[[@b67-enm-2020-35-2-227]\]. A clinical trial revealed that NKO-035 has high affinity for LAT1 (Japanese Registry of Clinical Trials, jRCTs051190057). Of these, ^18^F-FDOPA and ^11^C-MET have been assessed among TC patients \[[@b68-enm-2020-35-2-227],[@b69-enm-2020-35-2-227]\]. ^18^F-FDOPA PET/CT is a suitable modality for detecting metastatic, persistent, and residual MTC; however, ^18^F-FDG PET/CT may be considered for aggressive MTC in cases displaying signs of dedifferentiation or rapidly rising CEA levels \[[@b68-enm-2020-35-2-227],[@b69-enm-2020-35-2-227]\]. Thus far, ^11^C-MET PET has not been proven superior to ^18^F-FDG PET in detecting recurrent differentiated TC \[[@b70-enm-2020-35-2-227]\]. However, few studies have focused on amino acid transporters in TC. Further studies are required to determine the utility of amino acid transporter imaging in TC.

Boron neutron capture therapy
-----------------------------

Boron neutron capture therapy (BNCT) is an anticancer therapy using high linear energy transfer alpha particles. Particle radiation is generated by fission reactions when an irradiated thermal neutron beam collides with boron captured by a malignant tumor ([Fig. 1](#f1-enm-2020-35-2-227){ref-type="fig"}). The traveling distance of particle radiation is limited to approximately 5 to 9 μm, and it then disrupts only cancer cells capturing boron without damaging other cells around target cells \[[@b71-enm-2020-35-2-227],[@b72-enm-2020-35-2-227]\]. The success of BNCT depend on ^10^B compound concentration of tumor/normal tissue ratios (T/N ratio). This difficult task could be performed by synthesizing a boron compound that is selectively delivered by LAT1. Indeed, p-boronophenylalanine (BPA), a boron compound commonly used in BNCT, is incorporated in cancer cells through LAT1 \[[@b73-enm-2020-35-2-227]--[@b75-enm-2020-35-2-227]\], which serves as an optimal mediator for boron delivery. BNCT has achieved certain clinical outcomes in case of high T/N ratio in boron concentration; however, it requires a large-scale nuclear reactor to generate neutrons. Nonetheless, a compact accelerator has been developed as an alternative to a nuclear reactor, and it can be installed in a hospital, thus facilitating the easy application of BNCT \[[@b76-enm-2020-35-2-227]\]. Dagrosa et al. \[[@b77-enm-2020-35-2-227]--[@b79-enm-2020-35-2-227]\] reported the application of BNCT for undifferentiated TC *in vitro* and in an *in vivo* mouse model. However, the clinical advantages of BNCT in TC management remain unknown.

REGULATION OF LAT1
==================

MYC, a proto-oncogene, is upstream of LAT1. The consensus binding sequence of MYC is located at the LAT1 promoter \[[@b80-enm-2020-35-2-227]\]. Moreover, MYC knockdown downregulates LAT1 in human pancreatic cancer cell lines \[[@b80-enm-2020-35-2-227]\]. MYC is usually expressed at baseline levels in healthy adults \[[@b81-enm-2020-35-2-227]\]; however, MYC overexpression owing to gene amplification, gene translocation, or other gene mutations \[[@b82-enm-2020-35-2-227]\] results in malignant transformation. Notably, MYC is upregulated in patients with TC including ATC, and MYC overexpression promotes TC pathogenesis \[[@b83-enm-2020-35-2-227]--[@b86-enm-2020-35-2-227]\]. Therefore, MYC is a LAT1 regulator, partly even in TC.

Furthermore, hypoxia-inducible factor (HIF) 2 regulates LAT1. HIF2a, an isoform of the HIF family regulating responses to hypoxia, binds to the LAT1 promoter and upregulates LAT1 in renal carcinoma and neuronal cells \[[@b87-enm-2020-35-2-227],[@b88-enm-2020-35-2-227]\]. Exogenous HIF2a upregulation induces LAT1 expression in the lung and liver tissues, wherein LAT1 is generally downregulated \[[@b87-enm-2020-35-2-227]\]. Furthermore, aryl hydrocarbon receptor (AHR) binds to its consensus binding sequence in LAT1 and induces LAT1 expression in breast cancer cell lines \[[@b89-enm-2020-35-2-227]\]. The NOTCH signaling pathway and activating transcription factor 4 (ATF4) also be candidate an important upstream regulator of LAT1 in human T-cell acute lymphoblastic leukemia and prostate cancer, respectively \[[@b33-enm-2020-35-2-227],[@b90-enm-2020-35-2-227]\]. The knockdown or small molecule inhibition of EZH2, the epigenetic regulator enhancer of zeste homolog 2, leads to de-repression of RXRα resulting in reduced LAT1 expression in non-small cell lung cancer model \[[@b91-enm-2020-35-2-227]\]. However, the effect of these factors on LAT1 expression in TC is still unclear.

CONCLUSIONS
===========

Numerous studies have reported the crucial role of amino acids and their transporters in various cancers; however, relatively few studies have determined their potential in the clinical management of TC. A detailed understanding of amino acid metabolism in different cancers would facilitate the development of curative therapy for cancers. Amino acid transporters, especially LAT1, are potential targets for molecular-targeted therapy, imaging, and diagnosis in numerous cancers including TC. The clinical implications of amino acid transporters have recently been reported. Further studies are required to clarify potential molecular targets for treating TC.
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![Schematic representation of the nuclear capture reaction in Boron neutron capture therapy. On irradiation of the ^10^B compound, p-boronophenylalanine (BPA), with thermal neutrons, alpha particles and lithium nuclei are obtained, subsequently damaging cancer cells selectively. The track ranges of the two emitted particles within the body are approximately 5 to 9 μm, and this distance is not greater than the diameter of the cancer cells. The emitted particles thus damage only the cancer cell nuclei and do not approach adjacent normal cells. Therefore, damage is suppressed in normal cells, since they do not take up BPA via L-type amino acid transporter 1 (LAT1), and cancer cells are selectively damaged.](enm-2020-35-2-227f1){#f1-enm-2020-35-2-227}

###### 

Amino Acid Transporters Associated with Thyroid Cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Protein   Gene        Major substrates                                                   Co-activator   Expression in thyroid cancer                                           Outcome on overexpression
  --------- ----------- ------------------------------------------------------------------ -------------- ---------------------------------------------------------------------- ------------------------------------------------------------------------------------
  LAT1      *SLC7A5*    Leu, Ile, Val, Phe, Met, His, Tyr, Trp                             4F2hc/CD98     Upregulation in\                                                       Poor in\
                                                                                                           PTC \[[@b24-enm-2020-35-2-227]\]\                                      PTC \[[@b24-enm-2020-35-2-227],[@b25-enm-2020-35-2-227]\]\
                                                                                                           ATC \[[@b24-enm-2020-35-2-227],[@b26-enm-2020-35-2-227]\]\             ATC \[[@b26-enm-2020-35-2-227]\]
                                                                                                           MTC \[[@b27-enm-2020-35-2-227]\]                                      

  LAT2      *SLC7A8*    Ala, Asn, Cys, Gln, Gly, Ile, Leu, Met, Phe , Ser, Thr, Tyr, Val   4F2hc/CD98     Upregulation\                                                          No data
                                                                                                           PTC \[[@b30-enm-2020-35-2-227]\], MTC \[[@b27-enm-2020-35-2-227]\]\   
                                                                                                           No change in\                                                         
                                                                                                           FTC, ATC \[[@b30-enm-2020-35-2-227]\]                                 

  LAT3      *SLC43A1*   Leu, Ile, Val, Phe, Met                                            No             No data                                                                No data

  LAT4      *SLC43A2*   Leu, Ile, Val, Phe, Met                                            No             Downregulation in\                                                     No data
                                                                                                           PTC, FTC, PDTC, ATC \[[@b30-enm-2020-35-2-227]\]                      

  ASCT2     *SLC1A5*    Ala, Ser, Cys, Thr, Gln, Asn, Glu                                  No             Upregulation in\                                                       No change in\
                                                                                                           MTC \[[@b39-enm-2020-35-2-227]\]\                                      all[a](#tfn2-enm-2020-35-2-227){ref-type="table-fn"} \[[@b39-enm-2020-35-2-227]\]
                                                                                                           Nochange in\                                                          
                                                                                                           PTC, FTC, PDTC, ATC \[[@b39-enm-2020-35-2-227]\]                      

  ATB^0+^   *SLC6A14*   Ala, Ser, Cys, His, Met, Ile, Leu, Val, Phe, Tyr, Trp              No             No data                                                                No data

  xCT       *SLC7A11*   Gln                                                                4F2hc/CD98     No data                                                                Poor in\
                                                                                                                                                                                  PTC \[[@b25-enm-2020-35-2-227]\]

  CTR3      *SLC7A3*    Arg, Lys                                                           No             No data                                                                Poor in\
                                                                                                                                                                                  PTC \[[@b25-enm-2020-35-2-227]\]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LAT1, L-type amino acid transporter 1; His, histidine; Met, methionine; Leu, leucine; Ile, isoleucine, Val, valine; Phe, phenylalanine; Ala, alanine; Asn, asparagine; Cys, cysteine; Gln, glutamine; Gly glycine; Ser, serine; Thr, threonine; Trp, tryptophan; Tyr, tyrosine; Arg, arginine; Lys, lysine; PTC, papillary thyroid cancer; ATC, anaplastic thyroid cancer; ASCT, alanine-serine-cysteine transporter; MTC, medullary thyroid cancer; FTC, follicular thyroid cancer; PDTC, poorly differentiated thyroid cancer; ATB, amino acid transporter B; xCT, cystine/glutamate exchanger; CTR, cationic amino acid transporter.

The survival was calculated in thyroid cancer, in the following subtypes: PTC, FTC, MTC, PDTC, and ATC.

###### 

Studies Reporting the Role of LAT1 in Thyroid Cancer

                             Hafliger et al. \[[@b24-enm-2020-35-2-227]\]   Enomoto et al. \[[@b26-enm-2020-35-2-227]\]   Barollo et al. \[[@b27-enm-2020-35-2-227]\]   Shen et al. \[[@b25-enm-2020-35-2-227]\]
  -------------------------- ---------------------------------------------- --------------------------------------------- --------------------------------------------- ------------------------------------------
  Histology                  PTC, ATC                                       ATC                                           MTC                                           PTC
                                                                                                                                                                        
  Clinical sample analysis   mRNA                                           IHC                                           mRNA, IHC                                     mRNA
                                                                                                                                                                        
  Survival analysis          PTC                                            ATC                                                                                         
                                                                                                                                                                        
  *In vitro* study                                                                                                                                                      
   Inhibitors                JPH203                                                                                       JPH203, siRNA                                 
   Cell cycle analysis                                                      G0/G1 cell cycle arrest                                                                     
   Apoptosis analysis        TUNEL positive                                                                                                                             
                                                                                                                                                                        
  *In vivo* mouse study      Conditional KO                                 xenograft model                                                                             

LAT1, L-type amino acid transporter 1; PTC, papillary thyroid cancer; ATC, anaplastic thyroid cancer; MTC, medullary thyroid cancer; IHC, immunohistochemistry; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; KO, knock-out.
